Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Thyroid Eye Disease (TED)
- Main trialPhase 3
- “A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)”In the company’s words, NCT07211776 on ClinicalTrials.gov
Other drugs for Thyroid Eye Disease (TED)
- IBI311Innovent · Phase 3
- MHB018AMinghui Pharmaceutical (Hangzhou) Ltd · Phase 3
- KHN939Beijing Kanghong Biological Medicine Co., Ltd. · Phase 3
- LinsitinibSling Therapeutics, Inc. · Astellas · Phase 3
- TeprotumumabAmgen · Phase 3
- VRDN-003Viridian Therapeutics, Inc. · Phase 3
Coming up1
- 14 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 14 Mar 2027 | A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026